CLINICAL OPERATIONS & OUTSOURCING


“At the same time, I might draw your attention to a set of other related things that are more sectorspecific. Things lie ower rchase Agreements, where we can decarbonise the electrical supply, because we do use a lot of power. ooing at things lie the healthy buildings initiative, which is something that enentech has been doing. Theres a set of things abot resilience becase disaster response, its not only a business continuity issue in pharma; its everybody else who depends on the drugs, right?”


Big pharma puts its green cap on As the climate emergency has continued to embed itself into the priorities of the business community as well as the public consciosness, pharma companies  lie other sectors – have been busy setting targets and collaborating on sstainability initiatives. eid says the majority of IA member


companies have made specific pblic commitments on emissions reduction, often in line with the standards set by the Science- ased Targets initiative. ch of the sector reports its emissions and environmental impacts to the arbon isclosre roject to increase transparency with the pblic. And while IA doesnt yet mae


environmental commitments a condition of membership, Reid says “there is a possibility for future consideration of including the environment in its code of condct. On the supply chain side, there have been


efforts to wrangle some form of climate action ot of an endlessly comple networ of clients and vendors. The harmacetical pply hain Initiative, which was established by industry in 2006, sets standards for responsible supply chain management in terms of safety, social and environmental objectives. Sustainability ratings tools such as EcoVadis,


meanwhile, can help businesses in pharma and other sectors to access environmentally responsible supply chain partners while cutting down on manal de diligence. “It helps with your supply chain because


if your suppliers also get their rating, you dont have to spend so mch time doing all the audits and collecting all the materials,” says ontai.


eid, meanwhile, enthses abot IAs coharmacotewardship initiative to redce the impact of pharmaceutical products in the environment, as well as its circular economy networ and the A Indstry Alliance, which focses on the antimicrobial resistance crisis. ven clinical trials are looing to clean p their act throgh efforts by the lies of the stainable ealthcare oalition. n top of the organisations maing


sustainability in the pharma industry their eplicit mission, theres also the steady maret pressure that comes from larger drug companies setting standards for their suppliers  and as choichet has observed, its often the investors who have set the pace. “[Investors] were the ones seeing the


research on long-term value and outperformance for companies that manage their softer performance aspects more effectively, and pshing it, he says. eve been creating this wor on


 commnications gidance for taling to investors. The investors have fond that helpful to share with their earlier-stage portfolio companies, saying, ‘As you grow up, heres what yo shold be thining abot. ven venture capital people are starting to want to see that as part of the business gameplan for earlierstage companies. The maret isnt pshing for sstainability


standards entirely ot of the indness of its heart, of course – as investors have recognised, theres plenty of evidence that competent environmental management is entwined with a healthy bottom line. r crrent nderstanding of this linage


between environmental and financial performance is that environmental performance is usually achieved by reducing or eliminating wasteful activities – energy consumption, production waste, transportation, water consumption and so on – which reduces costs, says elhir.


Health implications: Pharma’s response to a changing climate As mch as big pharma, as a corporate networ with a globe-spanning supply chain, could be described as part of the problem when it comes to climate change, it is also undoubtedly part of the soltion  or at least the adaptation.


Outsourcing In Clinical Trials | 13


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72